Equifax After the Print: Analysts Diverge, Shorts Stay Small

Equifax has cleared its Q3 earnings hurdle with an 18% rally, and the question now is whether the post-print positioning tells a coherent story or a contradictory one.

The short side is not the story here. At 4.3% of the free float, short interest has barely moved since the collapse that preceded the October 20 print. The drop from roughly 7.4 million shares in early October to just over 5 million happened before the results, not after them. Since then, SI has crept up by less than 2% over the week, settling at 5.27 million shares. Borrow costs remain negligible at 0.44%. Availability is exceptionally loose, with more than 35 shares available for every one currently borrowed. There is no squeeze pressure here and no sign that fresh shorts are building conviction against the $176.54 close.

Options positioning has pivoted meaningfully since the pre-earnings crouch. The put/call ratio has dropped to 1.58, well below its 20-day average of 1.94 and nearly 1.6 standard deviations beneath that mean. For most of October, the ratio was running above 2.0, touching 2.21 on October 14. That elevated put demand dissolved into the print and has not returned. The post-earnings options market looks less defensive than it has at any point this quarter, which sits in reasonable alignment with a stock that just produced an 11% single-day gain.

The analyst reaction has split in a way that captures the tension in the story. Needham raised its target to $210 from $190, keeping Buy, reflecting the view that the quarter validated the bull case around workforce solutions and FICO pricing. Stifel, also maintaining Buy, cut its target to $217 from $235, a signal that the analyst sees the stock as having run through some of the upside already. BMO moved in the same direction as Stifel, raising its target to $175 from $160 while holding at Market Perform, a modest acknowledgment of improvement without conviction. The mean consensus target now sits at $198.40, implying about 12% further upside from current levels. That is a narrower cushion than the 22% the Street was modelling before the rally, and it follows a sustained period of downward revisions that ran from late September through mid-October. Bulls point to USIS revenue growth momentum and potential EBITDA margin expansion of roughly 100 basis points year-over-year. Bears keep returning to mortgage origination pressure, tighter lending standards, and lingering reputational risk from the 2017 data breach. The EPS momentum scores reflect that debate: the 90-day reading ranks in the 26th percentile, while the 12-month forward earnings revision score sits at the 74th percentile, a split between where estimates have been going recently and where they are expected to land.

One data point from the alt data layer is worth noting. Equifax's buyback spend in Q2 2026 came in at $300 million, according to SEC EDGAR XBRL filings compiled by the ORTEX Alt Data layer. That figure is 135% above the same quarter last year and is the largest Q2 buyback spend on record for the company going back to 2009. The buyback came at prices well below where the stock is trading today following the post-earnings move, making the capital allocation look well-timed in retrospect.

Separately, ORTEX forecasts a 52% probability that Equifax joins the CRSP US Small index at the December 2026 Quarterly Review, with the rank date falling on December 4. The stock needs to close above $179.86 to qualify under the index rule. At $176.54, that is 1.9% away. If inclusion were confirmed, index trackers would need to buy approximately $330 million worth of shares, equivalent to 1.2 days of normal trading volume. The same review carries a 50% probability of a share count decrease in the CRSP US Mid index, which would require $201 million of selling in the other direction. The two flows are not necessarily offsetting, as different tracker pools are involved, but the net mechanical pressure from December rebalancing will depend on which of these forecasts resolves as announced.

The nearest catalyst on the calendar is the next earnings event, currently scheduled for February 3, 2027. Between now and then, what to watch is whether the post-print analyst recalibration continues, specifically whether the target cuts that defined October have stabilised at these levels or whether the Street continues trimming as the mortgage rate backdrop becomes clearer heading into year-end.